Antitumor effects of anlotinib in thyroid cancer

Xianhui Ruan, Xianle Shi, Qiman Dong, Yang Yu, Xiukun Hou, Xinhao Song, Xi Wei, Lingyi Chen, Ming Gao

Research output: Contribution to journalArticle

Abstract

There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better understand the effect and efficacy of anlotinib against thyroid carcinoma cells in vitro and in vivo. We found that anlotinib inhibits the cell viability of papillary thyroid cancer and ATC cell lines, likely due to abnormal spindle assembly, G2/M arrest, and activation of TP53 upon anlotinib treatment. Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anticancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.

Original languageEnglish (US)
Pages (from-to)153-164
Number of pages12
JournalEndocrine-Related Cancer
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Thyroid Neoplasms
Clinical Trials, Phase I
Heterografts
Cell Survival
Thyroid Gland
Phosphotransferases
Therapeutics
Carcinoma
Cell Line
Growth
Neoplasms
In Vitro Techniques
Papillary Thyroid cancer
Anaplastic Thyroid Carcinoma

Keywords

  • Anlotinib
  • Apoptosis
  • Migration
  • Multi-kinase inhibitor
  • Thyroid cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Ruan, X., Shi, X., Dong, Q., Yu, Y., Hou, X., Song, X., ... Gao, M. (2019). Antitumor effects of anlotinib in thyroid cancer. Endocrine-Related Cancer, 26(1), 153-164. https://doi.org/10.1530/ERC-17-0558

Antitumor effects of anlotinib in thyroid cancer. / Ruan, Xianhui; Shi, Xianle; Dong, Qiman; Yu, Yang; Hou, Xiukun; Song, Xinhao; Wei, Xi; Chen, Lingyi; Gao, Ming.

In: Endocrine-Related Cancer, Vol. 26, No. 1, 01.01.2019, p. 153-164.

Research output: Contribution to journalArticle

Ruan, X, Shi, X, Dong, Q, Yu, Y, Hou, X, Song, X, Wei, X, Chen, L & Gao, M 2019, 'Antitumor effects of anlotinib in thyroid cancer' Endocrine-Related Cancer, vol. 26, no. 1, pp. 153-164. https://doi.org/10.1530/ERC-17-0558
Ruan X, Shi X, Dong Q, Yu Y, Hou X, Song X et al. Antitumor effects of anlotinib in thyroid cancer. Endocrine-Related Cancer. 2019 Jan 1;26(1):153-164. https://doi.org/10.1530/ERC-17-0558
Ruan, Xianhui ; Shi, Xianle ; Dong, Qiman ; Yu, Yang ; Hou, Xiukun ; Song, Xinhao ; Wei, Xi ; Chen, Lingyi ; Gao, Ming. / Antitumor effects of anlotinib in thyroid cancer. In: Endocrine-Related Cancer. 2019 ; Vol. 26, No. 1. pp. 153-164.
@article{bf58c41a9b0d403683cdc731f9b601b5,
title = "Antitumor effects of anlotinib in thyroid cancer",
abstract = "There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better understand the effect and efficacy of anlotinib against thyroid carcinoma cells in vitro and in vivo. We found that anlotinib inhibits the cell viability of papillary thyroid cancer and ATC cell lines, likely due to abnormal spindle assembly, G2/M arrest, and activation of TP53 upon anlotinib treatment. Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anticancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.",
keywords = "Anlotinib, Apoptosis, Migration, Multi-kinase inhibitor, Thyroid cancer",
author = "Xianhui Ruan and Xianle Shi and Qiman Dong and Yang Yu and Xiukun Hou and Xinhao Song and Xi Wei and Lingyi Chen and Ming Gao",
year = "2019",
month = "1",
day = "1",
doi = "10.1530/ERC-17-0558",
language = "English (US)",
volume = "26",
pages = "153--164",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "1",

}

TY - JOUR

T1 - Antitumor effects of anlotinib in thyroid cancer

AU - Ruan, Xianhui

AU - Shi, Xianle

AU - Dong, Qiman

AU - Yu, Yang

AU - Hou, Xiukun

AU - Song, Xinhao

AU - Wei, Xi

AU - Chen, Lingyi

AU - Gao, Ming

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better understand the effect and efficacy of anlotinib against thyroid carcinoma cells in vitro and in vivo. We found that anlotinib inhibits the cell viability of papillary thyroid cancer and ATC cell lines, likely due to abnormal spindle assembly, G2/M arrest, and activation of TP53 upon anlotinib treatment. Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anticancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.

AB - There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better understand the effect and efficacy of anlotinib against thyroid carcinoma cells in vitro and in vivo. We found that anlotinib inhibits the cell viability of papillary thyroid cancer and ATC cell lines, likely due to abnormal spindle assembly, G2/M arrest, and activation of TP53 upon anlotinib treatment. Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anticancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.

KW - Anlotinib

KW - Apoptosis

KW - Migration

KW - Multi-kinase inhibitor

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=85056943147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056943147&partnerID=8YFLogxK

U2 - 10.1530/ERC-17-0558

DO - 10.1530/ERC-17-0558

M3 - Article

VL - 26

SP - 153

EP - 164

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 1

ER -